CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...
Phase 3
Seville, Spain and 52 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Seville, Spain and 43 other locations
when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progr...
Phase 2
Sevilla, Spain and 40 other locations
and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndro...
Phase 1
Seville, Spain and 15 other locations
VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation...
Phase 3
Seville, Spain and 247 other locations
of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk...
Phase 1
Seville, Spain and 8 other locations
combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute...
Phase 3
Seville, Spain and 288 other locations
administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed ...
Phase 2
Sevilla, Spain and 36 other locations
monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodyspla...
Phase 1, Phase 2
Seville, Spain and 47 other locations
with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alteratio...
Phase 1
Seville, Spain and 45 other locations
Clinical trials
Research sites
Resources
Legal